Francesca Barone, Chief Scientific Officer at Candel Therapeutics, Inc. (CADL), bought 1,238 shares at $1.61 ($2K) on 2022-12-08, disclosed to the SEC on 2022-12-12.
Open-market purchase of $2k CADL by Chief Scientific Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Clearly above the average filing.
| Filing → |
| CADL | SELL | 2025-01-17 | $196K | — | Filing → |
| CADL | SELL | 2025-01-10 | $225K | — | Filing → |
| CADL | SELL | 2024-12-03 | $201K | — | Filing → |